The prevention of cervical cancer in Africa

Women's Health

Volumn 7, Issue 1, 2011, Pages 121-132

  Fiander, A N ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Africa; cervical cancer; cervical screening; HPV testing; HPV vaccination; prevention; visual inspection with acetic acid

Indexed keywords

ACETIC ACID; VIRUS DNA; WART VIRUS VACCINE;

AFRICA; ANTIBODY RESPONSE; CANCER GRADING; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; COLPOSCOPY; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; HEALTH PROGRAM; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; INTERMETHOD COMPARISON; NONHUMAN; PATIENT ADVOCACY; PATIENT EDUCATION; PHYSICAL DISABILITY; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SEROCONVERSION; SHELF LIFE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINE PRODUCTION; WART VIRUS;

ADOLESCENT; AFRICA SOUTH OF THE SAHARA; CHILD; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 78650657593     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.74     Document Type: Review

References (70)

1. Walraven G: Prevention of cervical cancer in Africa: a daunting task? Afr. J. Reprod. Health 7(2), 7-12 (2003).
2. Agosti JM, Goldie SJ: Introducing HPV vaccine in developing countries - key challenges and issues. N. Engl. J. Med. 356(19), 1908-1910 (2007).
3. WHO, UNFPA: Preparing for the introduction of HPV vaccines: policy and programme guidance for countries. Geneva, Switzerland (2006).
4. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol. 2(9), 533-543 (2001).
5. Parkin DM, Bray F: The burden of HPV-related cancers. Vaccine 24(Suppl. 3) S11-S25 (2006).
6. Peto J, Gilham C, Fletcher O, Matthews FE: The cervical cancer epidemic that screening has prevented in the UK. Lancet 364(9430), 249-256 (2004).
7. Barton MB, Frommer M, Shafiq J: Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet Oncol. 7(7), 584-595 (2006).
8. Walboomers JM, Meijer CJ: Do HPV negative cervical carcinomas exist? J. Pathol. 181, 253-254 (1997).
9. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88(1), 63-73 (2003).
10. von Krogh G: Management of anogenital warts (condylomata acuminata). Eur. J. Dermatol. 11(6), 598-603 (2001). (Pubitemid 33044469)
11. Peto J, Gilham C, Deacon J et al.: Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br. J. Cancer. 91(5), 942-953 (2004).
12. Stanley M: Cervical cancer vaccines: progress and prospects. Trends in Urology, Gynaecology & Sexual Health 11(6), 12-16 (2006).
13. Shepherd J, Peersman G, Weston R, Napuli I: Cervical cancer and sexual lifestyle: a systematic review of health education interventions targeted at women. Health Educ. Res. 15(6), 681-694 (2000).
14. Shepherd J, Weston R, Peersman G, Napuli IZ: Interventions for encouraging sexual lifestyles and behaviours intended to prevent cervical cancer. Cochrane Database Syst. Rev. 2, CD001035 (2000).
15. Manhart LE, Koutsky LA: Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex. Transm. Dis. 29(11), 725-735 (2002).
16. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl Acad. Sci. USA 89, 12180-12184 (1992).
17. Koutsky LA, Ault KA, Wheeler CM et al.: A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347(21), 1645-1651 (2002).
18. Harper D, Franco E, Wheeler C et al.: Efficacy of a bivalent L1 virus-like particle in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364, 1757-1765 (2004).
19. Harper DM, Franco EL, Wheeler CM et al.: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367(9518), 1247-1255 (2006).
20. Paavonen J, Jenkins D, Bosch FX et al.: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet 369(9580), 2161-2170 (2007).
21. Garland SM, Hernandez-Avila M, Wheeler CM et al: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356(19), 1928-1943 (2007).
22. FUTURE II study group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356(19), 1915-1927 (2007).
23. Villa LL: Quadrivalent human papillomavirus (HPV) type 6/11/16/18 L1 virus-like particle vaccine: first analysis of cross-protection against cervical intraepthelial neoplasia (CIN) and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18. EUROGIN Conference proceedings, 4-6 October 2007, Monaco (2007).
24. Harper DM: AS04-adjuvanted cervical cancer vaccine: clinical overview of efficacy, immunogenicity and safety in women 15-25 years of age. EUROGIN Monaco 4-6 October (2007).
25. Paavonen J, Naud P, Salmeron J et al.: Efficacy of human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA), final analysis of a double-blind, randomised study in young women. Lancet 374(9686), 301-314 (2009).
26. Brown DR, Kjaer SK, Sigurdsson K et al: The impact of quadrivalent human papillomavirus (HPV types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16- 26 years. J. Infect. Dis. 199(7), 926-935 (2009).
27. Stanley M: HPV vaccines: where are we now? J. Fam. Plann. Reprod. Healthcare 33(4), 227-229 (2007).
28. Fraser C, Tomassini JE, Xi L et al.: Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 25(21), 4324-4333 (2007).
29. Olsson SE, Villa LL, Costa RL et al.: Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25(26), 4931-4939 (2007).
30. WHO position paper on HPV vaccines. Vaccine 27(52), 7236-7237 (2009).
31. Block SL, Nolan T, Sattler C et al.: Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118(5), 2135-2145 (2006).
32. Pedersen C, Petaja T, Strauss G et al.: Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J. Adolesc. Health 40(6), 564-571 (2007).
33. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC: Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 285(24), 3107-3115 (2001).
34. Sankaranarayanan R, Shyamalakumary B, Wesley R et al.: Visual inspection with acetic acid in the early detection of cervical cancer and precursors. Int. J. Cancer 80(1), 161-163 (1999).
35. University of Zimbabwe: Visual inspection with acetic acid for cervical cancer screening: test qualities in a primary care setting. Lancet 353, 869-873 (1999).
36. Ngoma T, Muwonge R, Mwaiselage J, Kawegere J, Bukori P, Sankaranarayanan R: Evaluation of cervical visual inspection screening in Dar es Salaam, Tanzania. Int. J. Gynaecol. Obstet. 109(2), 100-104 (2010).
37. Denny L, Kuhn L, Pollack A, Wright TC: Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance. Cancer 94(6), 1699-1707 (2002).
38. Belinson JL, Pretorius RG, Zhang WH, Wu LY, Qiao YL, Elson P: Cervical cancer screening by simple visual inspection after acetic acid. Obstet. Gynecol. 98(3), 441-444 (2001).
39. Sankaranarayanan R, Basu P, Wesley RS et al.: Accuracy of visual screening for cervical neoplasia: results from an IARC multicentre study in India and Africa. Int. J. Cancer 110(6), 907-913 (2004). (Pubitemid 38758519)
40. Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S: A critical assessment of screening methods for cervical neoplasia. Int. J. Gynaecol. Obstet. 89(Suppl. 2), S4-S12 (2005).
41. Sangwa-Lugoma G, Mahmud S, Nasr SH et al.: Visual inspection as a cervical cancer screening method in a primary healthcare setting in Africa. Int. J. Cancer 119(6), 1389-1395 (2006).
42. Sankaranarayanan R, Nene BM, Dinshaw KA et al.: A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int. J. Cancer 116(4), 617-623 (2005).
43. Blumenthal PD, Lauterbach M, Sellors JW, Sankaranarayanan R: Training for cervical cancer prevention programs in low-resource settings: focus on visual inspection with acetic acid and cryotherapy. Int. J. Gynaecol. Obstet. 89(Suppl. 2), S30-S37 (2005).
44. Arbyn M, Sankaranarayanan R, Muwonge R et al.: Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int. J. Cancer 123(1), 153-160 (2008).
45. Denny L, Kuhn L, Pollack A, Wainwright H, Wright TC: Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer 89(4), 826-833 (2000). (Pubitemid 30658582)
46. Sankaranarayanan R, Esmy PO, Rajkumar R et al.: Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 370(9585), 398-406 (2007).
47. Sankaranarayanan R, Wesley R: A practical manuel on visual screening for cervical neoplasia. IARC Press, Lyon, France (2003).
48. Sellors J, Sankaranarayanan R: Colposcopy and treatment of cervical intraepithelial neoplasia: abeginners manual. IARC Press, Lyon, France (2003).
49. Qiao YL, Sellors JW, Eder PS et al.: A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. (10), 929-936 (2008).
50. Sankaranarayanan R, Nene BM, Shastri SS et al.: HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360(14), 1385-1394 (2009).
51. Schiffman M, Wacholder S: From India to the world-a better way to prevent cervical cancer. N. Engl. J. Med. 360(14), 1453-1455 (2009).
52. Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC, Jr: Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 294(17), 2173-2181 (2005).
53. Parham GP, Sahasrabuddhe VV, Mwanahamuntu MH et al.: Prevalence and predictors of squamous intraepithelial lesions of the cervix in HIV-infected women in Lusaka, Zambia. Gynecol Oncol. 103(3), 1017-1022 (2006).
54. Womack SD, Chirenje ZM, Gaffikin L et al.: HPV-based cervical cancer screening in a population at high risk for HIV infection. Int. J. Cancer 85(2), 206-210 (2000).
55. Kuhn L, Wang C, Tsai WY, Wright TC, Denny L: Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. AIDS 24(16), 2553-2561 (2010).
56. Mutyaba T, Mirembe F, Sandin S, Weiderpass E: Evaluation of see-see and treat strategy and role of HIV on cervical cancer prevention in Uganda. Reprod. Health 10, 7:4 (2010).
57. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD et al.: Cost-effectiveness of cervical-cancer screening in five developing countries. N. Engl. J. Med. 353(20), 2158-2168 (2005).
58. WHO: Control of cancer of the cervix uteri. A WHO meeting. Bull. World Health Organ. 64, 607-618 (1986).
59. IARC: Cervix cancer screening. IARC Press, Lyon, France (2005).
60. Cuzick J, Clavel C, Petry KU et al.: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119(5), 1095-1101 (2006).
61. Mayrand MH, Duarte-Franco E, Rodrigues I et al.: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357(16), 1579-1588 (2007).
62. Ronco G, Segnan N, Giorgi-Rossi P et al: Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J. Natl Cancer Inst. 98(11), 765-774 (2006). (Pubitemid 43983300)
63. Lorincz AT, Richart RM: Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch. Pathol. Lab. Med. 127(8), 959-968 (2003).
64. Kjaer S, Hogdall E, Frederiksen K et al.: The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 66(21), 10630-10636 (2006).
65. Wright TC Jr, Denny L, Kuhn L, Pollack A, Lorincz A: HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 283(1), 81-86 (2000).
66. Brinkman JA, Jones WE, Gaffga AM et al.: Detection of human papillomavirus DNA in urine specimens from human immunodeficiency virus-positive women. J. Clin. Microbiol. 40(9), 3155-3161 (2002).
67. Sasieni P, Adams J, Cuzick J: Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br. J. Cancer 89(1), 88-93 (2003).
68. Franceschi S, Cuzick J, Herrero R, Dillner J, Wheeler CM: EUROGIN (2008) roadmap on cervical cancer prevention. Int. J. Cancer 125(10), 2246-2255 (2009).
69. Michels KB, zur Hausen H: HPV vaccine for all. Lancet 374(9686), 268-270 (2009).
70. Kim JJ, Andres-Beck B, Goldie SJ: The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br. J. Cancer 97(9), 1322-1328 (2007).